Al-Shamsi says BCI has 30+ cancer specialists as DHA raises oncology standards

Humaid Al-Shamsi said Burjeel Cancer Institute has more than 30 oncology and hematology consultants and specialists, a scale marker that Dubai clinics, Abu Dhabi payers and UAE patients should now compare against licensed cancer-care pathways.

The OncoDaily item, published on 3 September 2026, reported Al-Shamsi's LinkedIn post on BCI's standalone cancer-centre model. The highest-stakes readers are COOs, CFOs and medical directors. For COOs, the issue is whether oncology services can coordinate same-day multidisciplinary review. For CFOs, the issue is prior authorisation, chemotherapy drug cost exposure and network steerage. For medical directors, the issue is governance around subspecialty tumour boards, paediatric oncology, bone marrow transplantation and palliative care.

"The only stand alone cancer center in the UAE lead by an Emarati Oncologist."
Humaid Al-Shamsi, CEO of Burjeel Cancer Institute and Chairman of Nexomic, via LinkedIn as reported by OncoDaily

Why Dubai operators should care

Dubai is the first market to watch because the Dubai Health Authority (DHA) announced advanced standards for oncology services on 25 June 2024. DHA said the standards regulate oncology services in Dubai health facilities and cover medical care, patient safety, quality KPIs, performance monitoring, multispecialty integration and patient outcomes.

The DHA announcement named Professor Humaid Al Shamsi, then described as Chairman of the Oncology Society at the Emirates Medical Association, as part of the workshop reviewing the standards with DHA. Emirates News Agency also named Dr. Marwan Al Mulla, CEO of DHA's Health Regulation Sector, and Dr. Hanan Obaid, Director of Health Policies and Standards at DHA, in the rollout.

For Dubai oncology providers, BCI's public positioning raises a practical benchmark: can a patient move through imaging review, pathology review, oncology consultation and treatment planning without repeated handoffs across unrelated providers? Clinics that refer out chemotherapy, radiation oncology or complex diagnostics should map the exact referral timeline. A five-day delay in pathology retrieval can matter more to the patient experience than a new waiting-room fit-out.

What clinics and insurers need to check

Abu Dhabi operators sit under the Department of Health Abu Dhabi (DOH), while providers in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain sit under the Ministry of Health and Prevention (MOHAP). BCI's base in Abu Dhabi makes DOH the immediate regulator for licensing and clinical governance. Dubai competitors still need to read the DHA standards because Dubai patients and insurers will compare pathways across emirates.

• Clinics: check whether the oncology licence, physician privileges and referral agreements cover medical oncology, hematology, paediatric oncology and palliative care.
• Insurers: for networks including Daman, Thiqa or Sukoon, confirm pre-authorisation rules for chemotherapy, immunotherapy, genomic tests and bone marrow transplantation before treatment starts.
• CFOs: request written estimates by drug name, cycle count, facility fee, infusion fee, pathology code and imaging code. Oncology bills can change when the regimen changes after tumour-board review.
• Medical directors: document tumour-board attendance, second-opinion rules, adverse-event escalation and palliative-care triggers in the patient record.

Cash prices should not be guessed. Patients should ask the licensed provider for an itemised estimate in AED and ask the insurer for a written benefit confirmation. Operators should benchmark those estimates against contracted tariff schedules, claim denials and average approval times. For cross-emirate referrals, the operational question is simple: which licensed entity owns the patient pathway on each date of care?

What this means for patients

BCI's message is a competitive signal for the UAE market: cancer care is moving toward larger, subspecialty-led programmes with same-day review and more visible clinical leadership. That puts pressure on smaller clinics to be clear about what they provide directly and what they refer out.

Patients in Dubai should first verify DHA-licensed oncology services. Patients in Abu Dhabi and Al Ain should verify DOH licensing. Patients in the northern emirates should verify MOHAP licensing. They should also ask whether the oncologist, pathology provider, imaging centre and infusion unit are all in network before the first treatment cycle.

The next test is measurable. UAE oncology providers will need to show waiting times, multidisciplinary review rates, treatment-authorisation speed and outcomes data. Operators that cannot publish those figures will compete mainly on convenience and payer access. Patients and referring doctors can compare licensed oncology providers through the UAE Open Healthcare Directory, which lists more than 12,386 licensed healthcare providers across 8 UAE cities and sources listings from official government registers.